Denali Q1 net loss $101.8M, cash $1.43B; reports pipeline progress and $500M PIPE

Denali Therapeutics Inc.

2024-Q1 EPS reported -$0.68

Net loss $101.8M vs $109.8M YoY; zero collaboration revenue vs $35.1M in Q1 2023.
R&D expense $107.0M, down from $128.8M; G&A $25.2M, down from $27.1M.
Completed $500M PIPE financing in February; raised cash to $1.43B.
Tividenofusp alfa (MPS II) shows sustained biomarker normalization; FDA may consider accelerated path.
Phase 1/2 for DNL126 (MPS IIIA) dosed; Phase 2/3 COMPASS enrollment expected to complete in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Denali Therapeutics Inc. reported the first quarter ended March 31, 2024 results: revenue There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended, net income Net loss was $101.8 million for the quarter ended March 31, 2024, compared to net loss of $109.8 million for the quarter.

Period: the first quarter ended March 31, 2024
Revenue: There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended
Net income: Net loss was $101.8 million for the quarter ended March 31, 2024, compared to net loss of $109.8 million for the quarter
Result: reported results

Exact text from the filing

Net loss was $101.8 million for the quarter ended March 31, 2024, compared to net loss of $109.8 million for the quarter ended March 31, 2023. There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended March 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Denali Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001714899-24-000120

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.